Amarantus Bioscience Holdings Inc (AMBS)

[Voices of Reason]

OK - I am glad you highlighted in bold letters the $100 million that RBCC points out. Of course, none of this is relavent to RBCC or AMBS - neither is a part of this $100 million drug trial being conducted by big drug companies.

The only related news stated in the press release is that "Rainbow BioSciences nears a deal with Amarantus BioSciences" - this is the same rehashed press release that we have been hearing for several months out of RBCC stating they are "near" or "hope" to have a deal in place "soon". What matters to investors is an "actual" deal.

The kicker is that RBCC considers itself a competitor to AMGN, CTIC, ABT, and AFFY - huh?? Under what criteria? Should assets, expertise, employees, revenue, capital, and an actual product be considered as criteria?